NCT03321695已完成不适用
An Observational Study of the Safety of Atezolizumab in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Percentage of Participants With Adverse Events
研究概览
简要总结
This is a study of the safety and effectiveness of atezolizumab in participants with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Participants also will have progressed on an appropriate approved targeted therapy if their tumor has epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene abnormalities treated in common clinical practice settings in Argentina.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed an informed consent form submitted to the Administración Nacional de Medicamentos Alimentos y Tecnología Médica (ANMAT)
- •Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) non-small cell lung cancer (NSCLC)
- •Have received at least one dose of atezolizumab as per local label and clinical practice
排除标准
- •Contraindicated atezolizumab therapy
结局指标
主要结局
Percentage of Participants With Adverse Events
时间窗: Up to approximately 2 years
次要结局
- Overall Survival (OS)(Up to approximately 2 years)
- Duration of Response (DOR)(Up to approximately 2 years)
- Progression-Free Survival (PFS)(Up to approximately 2 years)
- Percentage of Participants With a Confirmed Objective Response (ORR) of Complete Response (CR) or Partial Response (PR)(Up to approximately 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in ArgentinaUrothelial CarcinomaNCT03330886Hoffmann-La Roche13
招募中
2 期
Adebrelimab + Apatinib in SCLC Maintenance TherapySCLCNCT06475209Tang-Du Hospital60
已完成
不适用
A prospective observational study of Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000043463ational Cancer Center510
终止
2 期
Study of Atezolizumab in Relapsed or Refractory Hodgkin LymphomaHodgkin LymphomaNCT03120676Memorial Sloan Kettering Cancer Center3
已完成
2 期
Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)Non-Small Cell Lung CancerNCT03976518Gruppo Oncologico Italiano di Ricerca Clinica43